Your browser doesn't support javascript.
loading
Management of small subepithelial tumors by endoscopic banding without resection and single-incision needle-knife-assisted biopsy sampling: a prospective multicenter study.
Bas-Cutrina, Francesc; Loras, Carme; Pardo, Albert; Ballester-Clau, Raquel; Huertas, Carlos; Guarner-Argente, Carlos; Colan-Hernandez, Juan; Consiglieri, Claudia F; Andujar, Xavi; Vilanova-Serra, Magdalena; González-Huix, Ferran; Pardo-Grau, Laura; Maisterra, Sandra; Ruiz-Ramírez, Pablo; Garcia-Sumalla, Albert; Tebé, Cristian; Videla, Sebastià; Gornals, Joan B.
Afiliación
  • Bas-Cutrina F; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Department of Clinical Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Digestive D
  • Loras C; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Mútua de Terrassa, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Faculty of Health Sciences, Universitat Oberta de Cat
  • Pardo A; Department of Digestive Diseases, Hospital Universitari Joan XXIII, Tarragona, Spain.
  • Ballester-Clau R; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
  • Huertas C; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Doctor Josep Trueta, Girona, Spain.
  • Guarner-Argente C; Endoscopy Unit, Digestive Pathology Service, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Colan-Hernandez J; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
  • Consiglieri CF; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Department of Clinical Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • Andujar X; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Mútua de Terrassa, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
  • Vilanova-Serra M; Department of Digestive Diseases, Hospital Universitari Joan XXIII, Tarragona, Spain.
  • González-Huix F; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
  • Pardo-Grau L; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Doctor Josep Trueta, Girona, Spain.
  • Maisterra S; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Department of Clinical Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • Ruiz-Ramírez P; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Mútua de Terrassa, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
  • Garcia-Sumalla A; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Department of Clinical Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • Tebé C; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Statistics Advisory Service, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Videla S; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Department of Clinical Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Clinical Research and Clinical Trial Unit (UICEC-IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain.
  • Gornals JB; Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Department of Clinical Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Faculty of
Gastrointest Endosc ; 98(6): 911-921.e8, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37263361
BACKGROUND AND AIMS: Endoscopic band ligation (EBL) without resection combined with single-incision needle-knife (SINK) biopsy sampling may have a positive impact on small GI subepithelial tumor (SET) management, but the method needs to be tested. The aim was to evaluate the feasibility of this strategy in small-sized SETs. METHODS: This prospective multicenter observational cohort study in 7 centers included patients with SETs ≤15 mm (confirmed by EUS) between March 2017 and March 2020. The primary outcome was clinical success at 4 weeks, defined as complete SET disappearance on EUS. Secondary outcomes were long-term (1-year) clinical success, technical difficulty level, clinical impact, yield pathology, and safety. RESULTS: Of 273 patients screened, 122 (62.3% women; mean age, 60.9 ± 13.2 years) were included with SETs (mean size, 9 ± 2.8 mm; gastric location, 77%; superficial layer dependence, 63%). The primary endpoint was achieved in 73.6% of patients (95% confidence interval [CI], 64.8-81.2). At the 1-year follow-up, the success rate was 68.4% (95% CI, 59.1-76.8). A favorable clinical impact was observed in 97 cases (79.5%; 95% CI, 71.3-86.3). Pathology diagnosis was known in 70%. Potentially malignant lesions were present in 24.7%. The related adverse events rate was 4.1% (95% CI, 1.3-9.3; all mild: 2 bleeding, 2 abdominal pain). On multivariable analysis, the ≤10-mm SET group was associated with a greater success rate (1 year, 87%; relative risk, 5.07; 95% CI, 2.63-9.8) and clinical impact rate (92.7%; relative risk, 6.15; 95% CI, 2.72-13.93). CONCLUSIONS: EBL plus SINK biopsy sampling seems to be feasible and safe, and it may offer a favorable clinical impact in small-sized SETs. In particular, SETs ≤10 mm are the best candidates. (Clinical trial registration number: NCT03247231.).
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Gastrointestinales Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Gastrointest Endosc Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Gastrointestinales Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Gastrointest Endosc Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos